|
Title
Effect of simvastatin on CAD progression in patients with
normal levels of cholesterol .
Purpose
To evaluate the effect of simvastatin on CAD progression
in patients with normal levels of cholesterol .
Design
Randomized, double-blind, placebo-controlled study .
Patients
460 patients with normal levels (4.1-6.2 mmol/L) of cholesterol
and established CAD.
Follow-up
Four years
Treatment regimen
Simvastatin vs. placebo
Results
• Simvastatin slowed the progression of CAD.
• The need for revascularisation was reduced by 53.6%
in the simvastatin group; need for angioplasty was reduced
by 61.9%.
• Simvastatin caused a greater reduction in lipids as
compared to placebo (LDL: 30.9% reduction vs 3.5% increase
in placebo group; total cholesterol: 20.7% reduction vs 3.4%
increase with placebo; triglycerides: 9.7% reduction vs 8.8%
increase with placebo; HDL: 8.2% increase vs 3.1% in placebo).
• Addition of enalapril to the treatment regimen had
a neutral impact on the progression of CAD.
Conclusion
Simvastatin slows the progression of CAD in patients with
normal levels of cholesterol and established CAD .
|
